

Further Implementation of Recommendations from March 7, 2006 Pharmacy and Therapeutics Committee Meeting

Line Extensions:

Avandaryl®, Add to the MPPL and to the PDL in a category of Oral hypoglycemics combinations, without prior authorization

Bidil®, Add to the MPPL, without prior authorization

Fortical®, Add to the MPPL and to the PDL class, Osteoporosis Agents-Other with prior authorization

Review of Cardiac Classes on Preferred Drug List

ACE Inhibitors

Remove the prior authorization requirement from Tarka®, and create a new class, *Antihypertensive Combinations-ACEI-CCB* to include Lotrel® and Tarka®

Angiotensin Receptor Antagonists

These recommendations are still under review PDL remains the same at this time

Beta Blockers

No change to the current requirements as listed on the Preferred Drug List, (02/01/06)

Calcium Channel Blockers-Dihydropyridine

No change to the current requirements as listed on the Preferred Drug List, (02/01/06)

Calcium Channel Blockers-Non-Dihydropyridine

No change to the current requirements as listed on the Preferred Drug List, (02/01/06)

Lipotropic-Antihypertensive Combination

No change to the current requirements as listed on the Preferred Drug List, (02/01/06)

Lipotropics-Non-Statins: Fibrin Acid Derivatives

No change to the current requirements as listed on the Preferred Drug List, (02/01/06)

Lipotropics-Statins

These recommendations are still under review PDL remains the same at this time

Lipotropics-Niacin Derivatives

No change to the current requirements as listed on the Preferred Drug List, (02/01/06)

Lipotropics-Other

No change to the current status of Zetia®